{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T18:37:48Z","timestamp":1787769468536,"version":"build-2784847793"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,11,9]],"date-time":"2018-11-09T00:00:00Z","timestamp":1541721600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Strahlenther Onkol"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1007\/s00066-018-1391-2","type":"journal-article","created":{"date-parts":[[2018,11,9]],"date-time":"2018-11-09T08:33:15Z","timestamp":1541752395000},"page":"254-264","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Combined stereotactic body radiotherapy and trans-arterial chemoembolization as initial treatment in BCLC stage B\u2013C hepatocellular carcinoma","Kombinierte stereotaktische K\u00f6rperstamm-Strahlentherapie und transarterielle Chemoembolisation als Erstlinientherapie beim hepatozellul\u00e4ren Karzinom im BCLC-Stadium B\u2013C"],"prefix":"10.1007","volume":"195","author":[{"given":"C. L.","family":"Chiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0187-2703","authenticated-orcid":false,"given":"Mark K. H.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia S. Y.","family":"Yeung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connie H. M.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis A. S.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venus W. Y.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank C. S.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Blanck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,9]]},"reference":[{"issue":"2","key":"1391_CR1","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3322\/caac.20107","volume":"61","author":"A Jemal","year":"2011","unstructured":"Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. Ca Cancer J Clin 61(2):69\u201390. \n                    https:\/\/doi.org\/10.3322\/caac.20107","journal-title":"Ca Cancer J Clin"},{"issue":"03","key":"1391_CR2","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1055\/s-2007-1007122","volume":"19","author":"JM Llovet","year":"1999","unstructured":"Llovet JM, Br\u00fa C, Bruix J (1999) Prognosis of Hepatocellular carcinoma: The BCLC staging classification. Semin Liver Dis 19(03):329\u2013338. \n                    https:\/\/doi.org\/10.1055\/s-2007-1007122","journal-title":"Semin Liver Dis"},{"issue":"3","key":"1391_CR3","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/hep.24199","volume":"53","author":"J Bruix","year":"2011","unstructured":"Bruix J, Sherman M (2011) Management of hepatocellular carcinoma: An update. Hepatology 53(3):1020\u20131022. \n                    https:\/\/doi.org\/10.1002\/hep.24199","journal-title":"Hepatology"},{"issue":"7","key":"1391_CR4","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1053\/j.gastro.2007.04.061","volume":"132","author":"HB El-Serag","year":"2007","unstructured":"El-Serag HB, Rudolph KL (2007) Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology 132(7):2557\u20132576. \n                    https:\/\/doi.org\/10.1053\/j.gastro.2007.04.061","journal-title":"Gastroenterology"},{"issue":"5, Supplement 1","key":"1391_CR5","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1053\/j.gastro.2004.09.014","volume":"127","author":"G Fattovich","year":"2004","unstructured":"Fattovich G, Stroffolini T, Zagni I, Donato F (2004) Hepatocellular carcinoma in cirrhosis: Incidence and risk factors. Gastroenterology 127(5, Supplement 1):S35\u2013S50. \n                    https:\/\/doi.org\/10.1053\/j.gastro.2004.09.014","journal-title":"Gastroenterology"},{"issue":"7","key":"1391_CR6","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1053\/j.gastro.2014.02.032","volume":"146","author":"T Yau","year":"2014","unstructured":"Yau T, Tang VYF, Yao T\u2011J, Fan S\u2011T, Lo C\u2011M, Poon RTP (2014) Development of Hongkong liver cancer staging system with treatment stratification for patients with hepatocellular carcinoma. Gastroenterology 146(7):1691\u20131700. \n                    https:\/\/doi.org\/10.1053\/j.gastro.2014.02.032","journal-title":"Gastroenterology"},{"issue":"10 HCC","key":"1391_CR7","doi-asserted-by":"publisher","first-page":"e7635","DOI":"10.5812\/hepatmon.7635","volume":"12","author":"J Ng","year":"2012","unstructured":"Ng J, Wu J (2012) Hepatitis B\u2011 and hepatitis C\u2011related hepatocellular carcinomas in the United States: Similarities and differences. Hepat Mon 12(10 HCC):e7635. \n                    https:\/\/doi.org\/10.5812\/hepatmon.7635","journal-title":"Hepat Mon"},{"issue":"2","key":"1391_CR8","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s12072-010-9165-7","volume":"4","author":"M Omata","year":"2010","unstructured":"Omata M, Lesmana LA, Tateishi R, Chen P\u2011J, Lin S\u2011M, Yoshida H, Kudo M, Lee JM, Choi BI, Poon RTP, Shiina S, Cheng AL, Jia J\u2011D, Obi S, Han KH, Jafri W, Chow P, Lim SG, Chawla YK, Budihusodo U, Gani RA, Lesmana CR, Putranto TA, Liaw YF, Sarin SK (2010) Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 4(2):439\u2013474. \n                    https:\/\/doi.org\/10.1007\/s12072-010-9165-7","journal-title":"Hepatol Int"},{"issue":"5","key":"1391_CR9","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1053\/jhep.2002.33156","volume":"35","author":"C-M Lo","year":"2002","unstructured":"Lo C\u2011M, Ngan H, Tso W\u2011K, Liu C\u2011L, Lam C\u2011M, Poon RT-P, Fan S\u2011T, Wong J (2002) Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35(5):1164\u20131171. \n                    https:\/\/doi.org\/10.1053\/jhep.2002.33156","journal-title":"Hepatology"},{"issue":"9319","key":"1391_CR10","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1016\/S0140-6736(02)08649-X","volume":"359","author":"JM Llovet","year":"2002","unstructured":"Llovet JM, Real MI, Monta\u00f1a X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Sol\u00e0 R, Rod\u00e9s J, Bruix J (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A\u00a0randomised controlled trial. Lancet 359(9319):1734\u20131739. \n                    https:\/\/doi.org\/10.1016\/s0140-6736(02)08649-x","journal-title":"Lancet"},{"issue":"6","key":"1391_CR11","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1111\/j.1478-3231.2005.01170.x","volume":"25","author":"SJ Shim","year":"2005","unstructured":"Shim SJ, Seong J, Han KH, Chon CY, Suh CO, Lee JT (2005) Local radiotherapy as a\u00a0complement to incomplete transcatheter arterial chemoembolization in locally advanced hepatocellular carcinoma. Liver Int 25(6):1189\u20131196. \n                    https:\/\/doi.org\/10.1111\/j.1478-3231.2005.01170.x","journal-title":"Liver Int"},{"issue":"4","key":"1391_CR12","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J\u2011F, de Oliveira AC, Santoro A, Raoul J\u2011L, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz J\u2011F, Borbath I, H\u00e4ussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J (2008) Sorafenib in advanced hepatocellular carcinoma. N\u00a0Engl J Med 359(4):378\u2013390. \n                    https:\/\/doi.org\/10.1056\/NEJMoa0708857","journal-title":"N Engl J Med"},{"issue":"1","key":"1391_CR13","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","volume":"10","author":"A-L Cheng","year":"2009","unstructured":"Cheng A\u2011L, Kang Y\u2011K, Chen Z, Tsao C\u2011J, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang T\u2011S, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A\u00a0phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10(1):25\u201334. \n                    https:\/\/doi.org\/10.1016\/s1470-2045(08)70285-7","journal-title":"Lancet Oncol"},{"issue":"2","key":"1391_CR14","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1111\/j.1440-1746.2010.06329.x","volume":"26","author":"SL Chan","year":"2011","unstructured":"Chan SL, Mo FKF, Johnson PJ, Liem GS, Chan TC, Poon MC, Ma BBY, Leung TWT, Lai PBS, Chan ATC, Mok TSK, Yeo W (2011) Prospective validation of the Chinese University Prognostic Index and comparison with other staging systems for hepatocellular carcinoma in an Asian population. J\u00a0Gastroenterol Hepatol 26(2):340\u2013347. \n                    https:\/\/doi.org\/10.1111\/j.1440-1746.2010.06329.x","journal-title":"J Gastroenterol Hepatol"},{"issue":"4","key":"1391_CR15","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1200\/JCO.2007.14.3529","volume":"26","author":"RV Tse","year":"2008","unstructured":"Tse RV, Hawkins M, Lockwood G, Kim JJ, Cummings B, Knox J, Sherman M, Dawson LA (2008) Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J\u00a0Clin Oncol 26(4):657\u2013664. \n                    https:\/\/doi.org\/10.1200\/jco.2007.14.3529","journal-title":"J Clin Oncol"},{"issue":"13","key":"1391_CR16","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1200\/JCO.2012.44.1659","volume":"31","author":"A Bujold","year":"2013","unstructured":"Bujold A, Massey CA, Kim JJ, Brierley J, Cho C, Wong RKS, Dinniwell RE, Kassam Z, Ringash J, Cummings B, Sykes J, Sherman M, Knox JJ, Dawson LA (2013) Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J\u00a0Clin Oncol 31(13):1631\u20131639. \n                    https:\/\/doi.org\/10.1200\/jco.2012.44.1659","journal-title":"J Clin Oncol"},{"issue":"10","key":"1391_CR17","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1007\/s00066-014-0714-1","volume":"190","author":"F Sterzing","year":"2014","unstructured":"Sterzing F, Brunner TB, Ernst I, Baus WW, Greve B, Herfarth K, Guckenberger M (2014) Stereotactic body radiotherapy for liver tumors: Principles and practical guidelines of the DEGRO Working Group on Stereotactic Radiotherapy. Strahlenther Onkol 190(10):872\u2013881. \n                    https:\/\/doi.org\/10.1007\/s00066-014-0714-1","journal-title":"Strahlenther Onkol"},{"issue":"9","key":"1391_CR18","doi-asserted-by":"publisher","first-page":"4673","DOI":"10.1118\/1.3476463","volume":"37","author":"VYW Wong","year":"2010","unstructured":"Wong VYW, Tung SY, Ng AWY, Li FAS, Leung JOY (2010) Real-time monitoring and control on deep inspiration breath-hold for lung cancer radiotherapy\u2014Combination of ABC and external marker tracking. Med Phys 37(9):4673\u20134683. \n                    https:\/\/doi.org\/10.1118\/1.3476463","journal-title":"Med Phys"},{"issue":"4","key":"1391_CR19","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/j.ijrobp.2007.11.042","volume":"70","author":"JWH Wolthaus","year":"2008","unstructured":"Wolthaus JWH, Sonke J\u2011J, van Herk M, Belderbos JSA, Rossi MMG, Lebesque JV, Damen EMF (2008) Comparison of different strategies to use four-dimensional computed tomography in treatment planning for lung cancer patients. Int J Radiat Oncol Biol Phys 70(4):1229\u20131238. \n                    https:\/\/doi.org\/10.1016\/j.ijrobp.2007.11.042","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"1391_CR20","doi-asserted-by":"publisher","first-page":"e0174929","DOI":"10.1371\/journal.pone.0174929","volume":"12","author":"M Chan","year":"2017","unstructured":"Chan M, Chiang CL, Lee V, Cheung S, Leung R, Wong M, Lee F, Blanck O (2017) Target localization of 3D versus 4D cone beam computed tomography in lipiodol-guided stereotactic radiotherapy of hepatocellular carcinomas. PLoS ONE 12(4):e174929. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0174929","journal-title":"PLoS ONE"},{"issue":"2","key":"1391_CR21","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1007\/s00066-015-0929-9","volume":"192","author":"MKH Chan","year":"2016","unstructured":"Chan MKH, Lee V, Chiang CL, Lee FAS, Law G, Sin NY, Siu KL, Wong FCS, Tung SY, Luk H, Blanck O (2016) Lipiodol versus diaphragm in 4D-CBCT-guided stereotactic radiotherapy of hepatocellular carcinomas. Strahlenther Onkol 192(2):92\u2013101. \n                    https:\/\/doi.org\/10.1007\/s00066-015-0929-9","journal-title":"Strahlenther Onkol"},{"issue":"13","key":"1391_CR22","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1002\/cncr.30008","volume":"122","author":"A Takeda","year":"2016","unstructured":"Takeda A, Sanuki N, Tsurugai Y, Iwabuchi S, Matsunaga K, Ebinuma H, Imajo K, Aoki Y, Saito H, Kunieda E (2016) Phase 2 study of stereotactic body radiotherapy and optional transarterial chemoembolization for solitary hepatocellular carcinoma not amenable to resection and radiofrequency ablation. Cancer 122(13):2041\u20132049. \n                    https:\/\/doi.org\/10.1002\/cncr.30008","journal-title":"Cancer"},{"issue":"129","key":"1391_CR23","first-page":"31","volume":"61","author":"Y Honda","year":"2014","unstructured":"Honda Y, Kimura T, Aikata H, Nakahara T, Naeshiro N, Miyaki D, Nagaoki Y, Kawaoka T, Takaki S, Hiramatsu A, Waki K, Ishikawa M, Kakizawa H, Kenjo M, Awai K, Nagata Y, Chayama K (2014) Pilot study of stereotactic body radiation therapy combined with transcatheter arterial chemoembolization for small hepatocellular carcinoma. Hepatogastroenterology 61(129):31\u201336","journal-title":"Hepatogastroenterology"},{"issue":"2","key":"1391_CR24","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1111\/hpb.12331","volume":"17","author":"R Jacob","year":"2015","unstructured":"Jacob R, Turley F, Redden DT, Saddekni S, Aal AKA, Keene K, Yang E, Zarzour J, Bolus D, Smith JK, Gray S, White J, Eckhoff DE, DuBay DA (2015) Adjuvant stereotactic body radiotherapy following transarterial chemoembolization in patients with non-resectable hepatocellular carcinoma tumours of \u22653\u202fcm. HPB (Oxford) 17(2):140\u2013149. \n                    https:\/\/doi.org\/10.1111\/hpb.12331","journal-title":"HPB (Oxford)"},{"key":"1391_CR25","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1186\/s12885-016-2894-9","volume":"16","author":"T-S Su","year":"2016","unstructured":"Su T\u2011S, Lu H\u2011Z, Cheng T, Zhou Y, Huang Y, Gao Y\u2011C, Tang M\u2011Y, Jiang H\u2011Y, Lian Z\u2011P, Hou E\u2011C, Liang P (2016) Long-term survival analysis in combined transarterial embolization and stereotactic body radiation therapy versus stereotactic body radiation monotherapy for unresectable hepatocellular carcinoma \u30095\u202fcm. BMC Cancer 16:834. \n                    https:\/\/doi.org\/10.1186\/s12885-016-2894-9","journal-title":"BMC Cancer"},{"issue":"16","key":"1391_CR26","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.4254\/wjh.v7.i16.2009","volume":"7","author":"A Facciorusso","year":"2015","unstructured":"Facciorusso A, Licinio R, Muscatiello N, Di Leo A, Barone M (2015) Transarterial chemoembolization: Evidences from the literature and applications in hepatocellular carcinoma patients. World J Hepatol 7(16):2009\u20132019. \n                    https:\/\/doi.org\/10.4254\/wjh.v7.i16.2009","journal-title":"World J Hepatol"},{"issue":"6","key":"1391_CR27","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1016\/j.jhep.2012.07.025","volume":"57","author":"E Terzi","year":"2012","unstructured":"Terzi E, Golfieri R, Piscaglia F, Galassi M, Dazzi A, Leoni S, Giampalma E, Renzulli M, Bolondi L (2012) Response rate and clinical outcome of HCC after first and repeated cTACE performed on demand. J\u00a0Hepatol 57(6):1258\u20131267. \n                    https:\/\/doi.org\/10.1016\/j.jhep.2012.07.025","journal-title":"J Hepatol"},{"issue":"5","key":"1391_CR28","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1111\/j.1477-2574.2010.00183.x","volume":"12","author":"RE Schwarz","year":"2010","unstructured":"Schwarz RE, Abou-Alfa GK, Geschwind JF, Krishnan S, Salem R, Venook AP (2010) Nonoperative therapies for combined modality treatment of hepatocellular cancer: Expert consensus statement. HPB (Oxford) 12(5):313\u2013320. \n                    https:\/\/doi.org\/10.1111\/j.1477-2574.2010.00183.x","journal-title":"HPB (Oxford)"},{"issue":"1","key":"1391_CR29","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1002\/hep.28453","volume":"64","author":"R Lencioni","year":"2016","unstructured":"Lencioni R, de Baere T, Soulen MC, Rilling WS, Geschwind J\u2011FH (2016) Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data. Hepatology 64(1):106\u2013116. \n                    https:\/\/doi.org\/10.1002\/hep.28453","journal-title":"Hepatology"},{"issue":"6","key":"1391_CR30","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1001\/jamaoncol.2015.2189","volume":"1","author":"Y Huo","year":"2015","unstructured":"Huo Y, Eslick GD (2015) Transcatheter arterial chemoembolization plus radiotherapy compared with chemoembolization alone for hepatocellular carcinoma: A systematic review and meta-analysis. Jama Oncol 1(6):756\u2013765. \n                    https:\/\/doi.org\/10.1001\/jamaoncol.2015.2189","journal-title":"Jama Oncol"},{"issue":"13","key":"1391_CR31","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1200\/JCO.2012.48.2703","volume":"31","author":"TS Hong","year":"2013","unstructured":"Hong TS (2013) Radiotherapy for hepatocellular carcinoma with tumor vascular thrombus: Ready for prime time? J\u00a0Clin Oncol 31(13):1619\u20131620. \n                    https:\/\/doi.org\/10.1200\/jco.2012.48.2703","journal-title":"J Clin Oncol"},{"issue":"19","key":"1391_CR32","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1200\/JCO.2017.76.0892","volume":"36","author":"PKH Chow","year":"2018","unstructured":"Chow PKH, Gandhi M, Tan S\u2011B, Khin MW, Khasbazar A, Ong J, Choo SP, Cheow PC, Chotipanich C, Lim K, Lesmana LA, Manuaba TW, Yoong BK, Raj A, Law CS, Cua IHY, Lobo RR, Teh CSC, Kim YH, Jong YW, Han H\u2011S, Bae S\u2011H, Yoon H\u2011K, Lee R\u2011C, Hung C\u2011F, Peng C\u2011Y, Liang P\u2011C, Bartlett A, Kok KYY, Thng C\u2011H, Low AS-C, Goh ASW, Tay KH, Lo RHG, Goh BKP, Ng DCE, Lekurwale G, Liew WM, Gebski V, Mak KSW, Soo KC, Asia-Pacific Hepatocellular Carcinoma Trials Group (2018) SIRveNIB: Selective internal radiation therapy versus Sorafenib in asia-pacific patients with Hepatocellular carcinoma. J\u00a0Clin Oncol 36(19):1913\u20131921. \n                    https:\/\/doi.org\/10.1200\/jco.2017.76.0892","journal-title":"J Clin Oncol"},{"issue":"6","key":"1391_CR33","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1053\/j.gastro.2016.08.029","volume":"151","author":"R Salem","year":"2016","unstructured":"Salem R, Gordon AC, Mouli S, Hickey R, Kallini J, Gabr A, Mulcahy MF, Baker T, Abecassis M, Miller F, Yaghmai V, Sato K, Desai K, Thornburg B, Benson AB, Rademaker A, Ganger D, Kulik L, Lewandowski RJ (2016) Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 151(6):1155\u20131163. \n                    https:\/\/doi.org\/10.1053\/j.gastro.2016.08.029","journal-title":"Gastroenterology"},{"issue":"1","key":"1391_CR34","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1053\/j.gastro.2009.09.006","volume":"138","author":"R Salem","year":"2010","unstructured":"Salem R, Lewandowski RJ, Mulcahy MF, Riaz A, Ryu RK, Ibrahim S, Atassi B, Baker T, Gates V, Miller FH, Sato KT, Wang E, Gupta R, Benson AB, Newman SB, Omary RA, Abecassis M, Kulik L (2010) Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: A comprehensive report of long-term outcomes. Gastroenterology 138(1):52\u201364. \n                    https:\/\/doi.org\/10.1053\/j.gastro.2009.09.006","journal-title":"Gastroenterology"},{"key":"1391_CR35","volume-title":"RTOG 1112 protocol - RANDOMIZED PHASE III STUDY OF SORAFENIB VERSUS STEREOTACTIC BODY RADIATION THERAPY FOLLOWED BY SORAFENIB IN HEPATOCELLULAR CARCINOMA","author":"Radiation Therapy Oncology Group","year":"2012","unstructured":"Radiation Therapy Oncology Group (2012) RTOG 1112 protocol - RANDOMIZED PHASE III STUDY OF SORAFENIB VERSUS STEREOTACTIC BODY RADIATION THERAPY FOLLOWED BY SORAFENIB IN HEPATOCELLULAR CARCINOMA. \n                    https:\/\/www.rtog.org\/Portals\/0\/RTOG%20Broadcasts\/Attachments\/1112_master_w_update_5.7.13.pdf"},{"issue":"31","key":"1391_CR36","doi-asserted-by":"publisher","first-page":"3980","DOI":"10.1200\/JCO.2013.49.9202","volume":"31","author":"H Soliman","year":"2013","unstructured":"Soliman H, Ringash J, Jiang H, Singh K, Kim J, Dinniwell R, Brade A, Wong R, Brierley J, Cummings B, Zimmermann C, Dawson LA (2013) Phase II trial of palliative radiotherapy for hepatocellular carcinoma and liver metastases. J\u00a0Clin Oncol 31(31):3980\u20133986. \n                    https:\/\/doi.org\/10.1200\/jco.2013.49.9202","journal-title":"J Clin Oncol"},{"issue":"4","key":"1391_CR37","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.semradonc.2011.05.003","volume":"21","author":"C Guha","year":"2011","unstructured":"Guha C, Kavanagh BD (2011) Hepatic radiation toxicity: Avoidance and amelioration. Semin Radiat Oncol 21(4):256\u2013263. \n                    https:\/\/doi.org\/10.1016\/j.semradonc.2011.05.003","journal-title":"Semin Radiat Oncol"},{"issue":"4","key":"1391_CR38","doi-asserted-by":"publisher","first-page":"e0176118","DOI":"10.1371\/journal.pone.0176118","volume":"12","author":"G Oldrini","year":"2017","unstructured":"Oldrini G, Huertas A, Renard-Oldrini S, Taste-George H, Vogin G, Laurent V, Salleron J, Henrot P (2017) Tumor response assessment by MRI following stereotactic body radiation therapy for hepatocellular carcinoma. PLoS ONE 12(4):e176118. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0176118","journal-title":"PLoS ONE"},{"issue":"7","key":"1391_CR39","doi-asserted-by":"publisher","first-page":"e0133488","DOI":"10.1371\/journal.pone.0133488","volume":"10","author":"B Vincenzi","year":"2015","unstructured":"Vincenzi B, Di Maio M, Silletta M, D\u2019Onofrio L, Spoto C, Piccirillo MC, Daniele G, Comito F, Maci E, Bronte G, Russo A, Santini D, Perrone F, Tonini G (2015) Prognostic relevance of objective response according to EASL criteria and mRECIST criteria in hepatocellular carcinoma patients treated with loco-regional therapies: A literature-based meta-analysis. PLoS ONE 10(7):e133488. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0133488","journal-title":"PLoS ONE"},{"key":"1391_CR40","doi-asserted-by":"publisher","first-page":"153303381879021","DOI":"10.1177\/1533033818790217","volume":"17","author":"SK Schaub","year":"2018","unstructured":"Schaub SK, Hartvigson PE, Lock MI, H\u00f8yer M, Brunner TB, Cardenes HR, Dawson LA, Kim EY, Mayr NA, Lo SS, Apisarnthanarax S (2018) Stereotactic body radiation therapy for hepatocellular carcinoma: Current trends and controversies. Technol Cancer Res Treat 17:1533033818790217. \n                    https:\/\/doi.org\/10.1177\/1533033818790217","journal-title":"Technol Cancer Res Treat"},{"key":"1391_CR41","doi-asserted-by":"publisher","DOI":"10.1007\/s00066-017-1256-0","author":"E Gkika","year":"2018","unstructured":"Gkika E, Bettinger D, Krafft L, Schultheiss M, Neeff HP, Maruschke L, Schulenburg M, Adebahr S, Kirste S, Nestle U, Thimme R, Grosu A\u2011L, Brunner TB (2018) The role of albumin\u2013bilirubin grade and inflammation-based index in patients with hepatocellular carcinoma treated with stereotactic body radiotherapy. Strahlenther Onkol. \n                    https:\/\/doi.org\/10.1007\/s00066-017-1256-0","journal-title":"Strahlenther Onkol"}],"container-title":["Strahlentherapie und Onkologie"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00066-018-1391-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-018-1391-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-018-1391-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,8]],"date-time":"2019-11-08T19:05:54Z","timestamp":1573239954000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00066-018-1391-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,9]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["1391"],"URL":"https:\/\/doi.org\/10.1007\/s00066-018-1391-2","relation":{},"ISSN":["0179-7158","1439-099X"],"issn-type":[{"value":"0179-7158","type":"print"},{"value":"1439-099X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,9]]},"assertion":[{"value":"23 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.L.\u00a0Chiang, M.K.H.\u00a0Chan, C.S.Y.\u00a0Yeung, C.H.M.\u00a0Ho, F.A.S.\u00a0Lee, V.W.Y.\u00a0Lee, F.C.S.\u00a0Wong, and O.\u00a0Blanck declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}